BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38411373)

  • 21. Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071.
    Piperno-Neumann S; Larkin J; Carvajal RD; Luke JJ; Schwartz GK; Hodi FS; Sablin MP; Shoushtari AN; Szpakowski S; Chowdhury NR; Brannon AR; Ramkumar T; de Koning L; Derti A; Emery C; Yerramilli-Rao P; Kapiteijn E
    Mol Cancer Ther; 2020 Apr; 19(4):1031-1039. PubMed ID: 32029634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives.
    Croce M; Ferrini S; Pfeffer U; Gangemi R
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31216772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma.
    Ewens KG; Lalonde E; Richards-Yutz J; Shields CL; Ganguly A
    BMC Cancer; 2018 Nov; 18(1):1172. PubMed ID: 30477459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Uveal melanoma: physiopathology and new in situ-specific therapies.
    Souto EB; Zielinska A; Luis M; Carbone C; Martins-Gomes C; Souto SB; Silva AM
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):15-32. PubMed ID: 31079217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metastatic Disease in Polyploid Uveal Melanoma Patients Is Associated With BAP1 Mutations.
    Yavuzyigitoglu S; Mensink HW; Smit KN; Vaarwater J; Verdijk RM; Beverloo B; Brüggenwirth HT; van Marion R; Dubbink HJ; Paridaens D; Naus NC; de Klein A; Kiliç E;
    Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):2232-9. PubMed ID: 27116551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. YAP/TAZ Activation Drives Uveal Melanoma Initiation and Progression.
    Li H; Li Q; Dang K; Ma S; Cotton JL; Yang S; Zhu LJ; Deng AC; Ip YT; Johnson RL; Wu X; Punzo C; Mao J
    Cell Rep; 2019 Dec; 29(10):3200-3211.e4. PubMed ID: 31801083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma.
    Li Y; Yang J; Zhang Q; Xu S; Sun W; Ge S; Xu X; Jager MJ; Jia R; Zhang J; Fan X
    Oncogene; 2022 Jul; 41(27):3539-3553. PubMed ID: 35697803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The oncolytic virus H101 combined with GNAQ siRNA-mediated knockdown reduces uveal melanoma cell viability.
    Li Y; He J; Qiu C; Shang Q; Qian G; Fan X; Ge S; Jia R
    J Cell Biochem; 2019 Apr; 120(4):5766-5776. PubMed ID: 30320917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
    Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
    Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma.
    Dono M; Angelini G; Cecconi M; Amaro A; Esposito AI; Mirisola V; Maric I; Lanza F; Nasciuti F; Viaggi S; Gualco M; Bandelloni R; Truini M; Coviello DA; Zupo S; Mosci C; Pfeffer U
    Br J Cancer; 2014 Feb; 110(4):1058-65. PubMed ID: 24423917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
    Ambrosini G; Sawle AD; Musi E; Schwartz GK
    Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolutionary Routes in Metastatic Uveal Melanomas Depend on
    Rodrigues M; Mobuchon L; Houy A; Alsafadi S; Baulande S; Mariani O; Marande B; Ait Rais K; Van der Kooij MK; Kapiteijn E; Gassama S; Gardrat S; Barnhill RL; Servois V; Dendale R; Putterman M; Tick S; Piperno-Neumann S; Cassoux N; Pierron G; Waterfall JJ; Roman-Roman S; Mariani P; Stern MH
    Clin Cancer Res; 2019 Sep; 25(18):5513-5524. PubMed ID: 31227496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma.
    Marseglia M; Amaro A; Solari N; Gangemi R; Croce E; Tanda ET; Spagnolo F; Filaci G; Pfeffer U; Croce M
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uveal Melanomas with SF3B1 Mutations: A Distinct Subclass Associated with Late-Onset Metastases.
    Yavuzyigitoglu S; Koopmans AE; Verdijk RM; Vaarwater J; Eussen B; van Bodegom A; Paridaens D; Kiliç E; de Klein A;
    Ophthalmology; 2016 May; 123(5):1118-28. PubMed ID: 26923342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Driver mutations in
    García-Mulero S; Fornelino R; Punta M; Lise S; Varela M; Del Carpio LP; Moreno R; Costa-García M; Rieder D; Trajanoski Z; Gros A; Alemany R; Piulats JM; Sanz-Pamplona R
    Oncoimmunology; 2023; 12(1):2261278. PubMed ID: 38126027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uveal melanoma hepatic metastases mutation spectrum analysis using targeted next-generation sequencing of 400 cancer genes.
    Luscan A; Just PA; Briand A; Burin des Roziers C; Goussard P; Nitschké P; Vidaud M; Avril MF; Terris B; Pasmant E
    Br J Ophthalmol; 2015 Apr; 99(4):437-9. PubMed ID: 25361747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent advances in uveal melanoma treatment.
    Álvarez-Rodríguez B; Latorre A; Posch C; Somoza Á
    Med Res Rev; 2017 Nov; 37(6):1350-1372. PubMed ID: 28759124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours.
    Johansson PA; Brooks K; Newell F; Palmer JM; Wilmott JS; Pritchard AL; Broit N; Wood S; Carlino MS; Leonard C; Koufariotis LT; Nathan V; Beasley AB; Howlie M; Dawson R; Rizos H; Schmidt CW; Long GV; Hamilton H; Kiilgaard JF; Isaacs T; Gray ES; Rolfe OJ; Park JJ; Stark A; Mann GJ; Scolyer RA; Pearson JV; van Baren N; Waddell N; Wadt KW; McGrath LA; Warrier SK; Glasson W; Hayward NK
    Nat Commun; 2020 May; 11(1):2408. PubMed ID: 32415113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review.
    Goh AY; Layton CJ
    Clin Exp Ophthalmol; 2016 Aug; 44(6):509-19. PubMed ID: 26601795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for
    Paradis JS; Acosta M; Saddawi-Konefka R; Kishore A; Gomes F; Arang N; Tiago M; Coma S; Lubrano S; Wu X; Ford K; Day CP; Merlino G; Mali P; Pachter JA; Sato T; Aplin AE; Gutkind JS
    Clin Cancer Res; 2021 Jun; 27(11):3190-3200. PubMed ID: 33568347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.